Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
17 Jul 2020
Historique:
received: 28 05 2020
revised: 04 07 2020
accepted: 15 07 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 17 2 2021
Statut: epublish

Résumé

Angiogenesis and the expression of vascular endothelial growth factor (VEGF) are increased in renal cell carcinoma (RCC). Transglutaminase 2 (TGase 2), which promotes angiogenesis in endothelial cells during wound healing, is upregulated in RCC. Tumor angiogenesis involves three domains: cancer cells, the extracellular matrix, and endothelial cells. TGase 2 stabilizes VEGF in the extracellular matrix and promotes VEGFR-2 nuclear translocation in endothelial cells. However, the role of TGase 2 in angiogenesis in the cancer cell domain remains unclear. Hypoxia-inducible factor (HIF)-1α-mediated VEGF production underlies the induction of angiogenesis in cancer cells. In this study, we show that p53 downregulated HIF-1α in RCC, and p53 overexpression decreased VEGF production. Increased TGase 2 promoted angiogenesis by inducing p53 degradation, leading to the activation of HIF-1α. The interaction of HIF-1α and p53 with the cofactor p300 is required for stable transcriptional activation. We found that TGase 2-mediated p53 depletion increased the availability of p300 for HIF-1α-p300 binding. A preclinical xenograft model suggested that TGase 2 inhibition can reverse angiogenesis in RCC.

Identifiants

pubmed: 32708896
pii: ijms21145042
doi: 10.3390/ijms21145042
pmc: PMC7404067
pii:
doi:

Substances chimiques

HIF1A protein, human 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
Tumor Suppressor Protein p53 0
E1A-Associated p300 Protein EC 2.3.1.48
EP300 protein, human EC 2.3.1.48
Protein Glutamine gamma Glutamyltransferase 2 EC 2.3.2.13
Transglutaminases EC 2.3.2.13
GTP-Binding Proteins EC 3.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Cancer Center
ID : 1910060-2
Pays : Republic of Korea

Références

Genes Dev. 2000 Jan 1;14(1):34-44
pubmed: 10640274
J Urol. 1997 Apr;157(4):1482-6
pubmed: 9120987
Biochem J. 2004 May 15;380(Pt 1):289-95
pubmed: 14992692
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
Cell Death Dis. 2016 Mar 31;7:e2163
pubmed: 27031960
J Cancer Res Clin Oncol. 2014 May;140(5):757-67
pubmed: 24610445
Cancers (Basel). 2018 Nov 19;10(11):
pubmed: 30463244
Biomol Ther (Seoul). 2019 Jan 31;27(1):34-40
pubmed: 30231606
J Biol Chem. 2005 Jun 24;280(25):23675-83
pubmed: 15849356
Science. 1987 Jan 23;235(4787):442-7
pubmed: 2432664
Biochem J. 2010 Apr 14;427(3):467-75
pubmed: 20156196
Exp Cell Res. 2006 Oct 1;312(16):2973-82
pubmed: 16914140
Nat Commun. 2017 Feb 16;8:14450
pubmed: 28205552
Genes Dev. 1995 Sep 1;9(17):2170-83
pubmed: 7657168
Cell Death Dis. 2016 Apr 21;7:e2200
pubmed: 27100894
Mol Cell. 2001 Apr;7(4):811-22
pubmed: 11336704
J Biol Chem. 2015 Aug 28;290(35):21365-75
pubmed: 26160175
Cancer Res. 1994 Aug 1;54(15):4233-7
pubmed: 7518352
Nature. 1997 Jun 19;387(6635):819-23
pubmed: 9194564
Adv Enzymol Relat Areas Mol Biol. 1983;54:1-56
pubmed: 6133417
Cancer. 1976 Dec;38(6):2469-80
pubmed: 1000477
FASEB J. 1999 Oct;13(13):1787-95
pubmed: 10506581
Nature. 1997 Jun 19;387(6635):823-7
pubmed: 9194565
Gut. 2003 Feb;52(2):159-61
pubmed: 12524388
Amino Acids. 2017 Mar;49(3):489-500
pubmed: 27394141
FASEB J. 2013 Sep;27(9):3487-95
pubmed: 23704086
Trends Biochem Sci. 2015 Aug;40(8):425-34
pubmed: 26032560
J Biol Chem. 1998 May 15;273(20):11995-8
pubmed: 9575138
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12969-73
pubmed: 8917528
FASEB J. 2019 Feb;33(2):2327-2342
pubmed: 30285580
Biol Reprod. 2013 Oct 17;89(4):88
pubmed: 23966323
J Pathol Transl Med. 2015 Jan;49(1):37-43
pubmed: 25812656
Nat Med. 1997 Jul;3(7):797-801
pubmed: 9212111
Int J Mol Sci. 2020 Apr 03;21(7):
pubmed: 32260198
J Biol Chem. 2009 Aug 14;284(33):22041-7
pubmed: 19542224
World J Urol. 2015 Oct;33(10):1553-60
pubmed: 25515319
Cancer Res. 2005 May 15;65(10):3967-79
pubmed: 15899784

Auteurs

Seon-Hyeong Lee (SH)

Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea.

Joon Hee Kang (JH)

Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.

Ji Sun Ha (JS)

Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.

Jae-Seon Lee (JS)

Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.

Su-Jin Oh (SJ)

Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.

Hyun-Jung Choi (HJ)

Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.

Jaewhan Song (J)

Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea.

Soo-Youl Kim (SY)

Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH